FMA
MYGN icon

Fiduciary Management Associates’s Myriad Genetics MYGN Stock Holding History

Fiduciary Management Associates’s Portfolio MYGN Stock Details MYGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q1 		– Sell
-403,460
Closed -$17.4M – 114
2015
Q4 		$17.4M Buy
+403,460
New +$17M 1.02% 71

Other funds holding MYGN

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
SCM
Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
IAM
Iridian Asset Management Westport, Connecticut $247M AUM 20.65% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
RIM
RS Investment Management San Francisco, California $9.73B AUM 3.24% 1-Year Est. Return
FCM
Frontier Capital Management Boston, Massachusetts $9.73B AUM 55.65% 1-Year Est. Return

Fiduciary Management Associates's MYGN Position: Q1 2016 in Review

Fiduciary Management Associates sold out of Myriad Genetics (MYGN) in Q1 2016, closing a stake of 403,460 shares — an estimated $17.4M sold.

Fiduciary Management Associates first reported a position in MYGN in Q4 2015 and held it in 1 quarter. The position peaked at $17.4M in Q4 2015. 233 funds tracked by Wall St. Rank hold MYGN as of Q1 2016.

  • Fiduciary Management Associates reported no remaining Myriad Genetics position as of Q1 2016 after selling out during the quarter.
  • Fiduciary Management Associates sold 403,460 Myriad Genetics shares in Q1 2016, an estimated $17.4M.
  • Fiduciary Management Associates first reported a position in Myriad Genetics in Q4 2015 and held it in 1 quarter.
  • Fiduciary Management Associates's Myriad Genetics position peaked at $17.4M in Q4 2015.
  • 233 funds tracked by Wall St. Rank held Myriad Genetics as of Q1 2016.

Based on Fiduciary Management Associates's 13F filing for Q1 2016, filed 4 May 2016.